Revalesio to Present New Parkinson’s Data at the American Academy of Neurology “Future of Neuroscience” Conference

Researchers from Rush University and Revalesio Corporation will be presenting two studies related to developing novel treatments for neuro-inflammatory disease at the Annual Meeting of the American Academy of Neurology (AAN), April 21-28, 2012 in New Orleans, Louisiana.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Tacoma, Wash. (PRWEB) April 25, 2012

Researchers from Rush University and Revalesio Corporation will be presenting two studies related to developing novel treatments for neuro-inflammatory disease at the Annual Meeting of the American Academy of Neurology (AAN), April 21-28, 2012 in New Orleans, Louisiana.

The first presentation demonstrates that Revalesio’s lead product, RNS60, inhibits the production of inflammatory proteins and chemicals in brain cells known as glial cells. The anti-inflammatory and neuro-protective activity of RNS60 is mediated via production of a protein called IkBα, a key regulator of inflammatory activity. Treatment with RNS60 attenuated the expression of the pro-inflammatory protein inducible nitric oxide synthase (iNOS) in the brain, protected dopaminergic neurons, and improved motor functions in an animal model of Parkinson’s disease. This presentation has been selected for the “Future of Neuroscience” conference, a special one-day event at the AAN meeting, on April 27.

The second presentation demonstrates that RNS60 increases the relative proportion of white blood cells called T-regulatory cells (Tregs) in a rodent model of Multiple Sclerosis (MS) via its effect on production of iNOS and nitric oxide. Tregs play a vital role in maintaining a balanced immune response. The study also showed that RNS60 shifted the immune response of lymph node cells from a Th17 and Th1 type to a Th2 type. Moreover, RNS60 suppressed the expression of iNOS and of another pro-inflammatory molecule, interleukin-1β, and normalized myelin gene expression in the central nervous system. These findings demonstrate a disease-modifying activity of RNS60 in this model.

Cumulatively, these data show that RNS60 has the potential to act as a novel immunomodulatory agent both within the central nervous system and in the periphery. These findings are particularly relevant to the potential future treatment of MS and other neuroinflammatory diseases including Parkinson’s disease and Alzheimer’s disease.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Bruce Buskirk
253-926-5567
contact(at)revalesio(dot)com.


Contact